Connect with us


Medical cannabis with reduced VAT will be available in pharmacies across Poland

Aurora Polska managed to convince the Polish government to reduce VAT on medical cannabis from 23% to 8%. A year ago, Spectrum Therapeutics also tried to pursue authorities on this issue. Reducing the VAT on medical cannabis will help to lower the price of this medicine slightly, but not enough to make it affordable for everyone, including the poorest patients.



This picture show a persona using a CDB oil.

Medical cannabis will be cheaper in Polish pharmacies, thanks to the reduction of VAT from 23% to 8%. Since April, Aurora Polska has been seeking a lower tax rate. These are not the first such attempts by medical cannabis producers to reduce VAT. In the end, however, they succeeded and patients will pay less for the medicine than before.

So far, people who needed medical cannabis to release their pain, had to pay $16 – $18.8 (60 – 70 PLN) per gram. Soon, this price will be lower, due to the reduction of the VAT rate, which until now has been 23% for products from all manufacturers.

Spectrum Therapeutics was the first company to try to reduce VAT to 8% a year ago. Unfortunately, without any effect. Only now Aurora Polska has managed to do so and has applied for lower VAT since April this year.

If you want to find why medical cannabis will be cheaper in pharmacies across Poland, how several cannabis companies tried to convince the Government to reduce the VAT on medical cannabis, and to read the most important cannabis news in the world, download for free the mobile app.

Medical cannabis will be cheaper in Poland

After the application submitted by Aurora Polska, the goal was achieved and the VAT was reduced on three products. The 8% VAT will include the following products:

Aurora Cannabis Flos 20/1 (20% THC, 1% CBD)

Aurora Cannabis Flos 8/8 (8% THC, 8% CBD)

Aurora Cannabis Flos 1/12 (1% THC, 12% CBD)

At the moment, the third of these products is available in pharmacies, but the other two are to be available in a few days. Aurora Polska has already contacted medical cannabis wholesalers in order to reduce the price of medicines. These have already confirmed the price reduction, which should result in patients paying less in pharmacies than before.

The availability of medical cannabis will increase

The high price of medical cannabis and thus its limited availability to patients has been repeatedly reimbursed by Jarosław Sachajko, member of KUKIZ’15. In one of the speeches at the June conference, Sachajko emphasized that without easing the regulations on possessing small amounts of cannabis, and allowing people to grow their own plants, there is no point in counting on medical cannabis patients being able to heal themselves normally.

He emphasized this during one of the conferences dedicated to hemp.

“Medical cannabis is very rarely prescribed by doctors for economic reasons. Patients are simply poor and cannot afford such expensive purchases. A chemical medicine often costs several zlotys and one gram of medical cannabis is several dozen zlotys,” said Jarosław Sachajko.

Reducing the VAT on medical cannabis will help to lower the price of this medicine slightly, but not enough to make it affordable for everyone, including the poorest patients.

Another activity of MP Sachajko in favor of the hemp industry was the idea of ​​easing sanctions against growers of industrial hemp. During the February session of the parliamentary subcommittee on bioeconomy and innovation in agriculture, Sachajko submitted an interpellation on behalf of hemp growers.


(Featured image by Erin_Hinterland via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in CANNABIS NEWS, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Michael Jermaine Cards is a business executive and a financial journalist, with a focus on IT, innovation and transportation, as well as crypto and AI. He writes about robotics, automation, deep learning, multimodal transit, among others. He updates his readers on the latest market developments, tech and CBD stocks, and even the commodities industry. He does management consulting parallel to his writing, and has been based in Singapore for the past 15 years.